Simple Blood Test Can Detect Predictive Biomarker for Cognitive Impairment and Dementia

Ergothioneine (ET) is a unique diet-derived compound discovered more than 100 years ago by Charles Tanret. However, it was only in 2005 when scientists discovered a transporter specific for ET that facilitates the uptake and accumulation of ET in the body. Now, a new study has revealed that low levels of ET in blood plasma may predict an increased risk of cognitive impairment and dementia, suggesting possible therapeutic or early screening measures for cognitive impairment and dementia in the elderly.

A team of researchers from the National University of Singapore (NUS, Singapore) demonstrated that ET is avidly retained in the human body following oral supplementation, and in preclinical models, ET is transported to almost all organs, although higher levels can be found in specific cells and tissues such as the blood cells, eyes, liver, lungs, and even the brain. Their earlier work demonstrated the potent antioxidant properties of ET and later its ability to protect cells from a range of different forms of stress and toxins. As its main dietary source is in mushrooms, it was found that increasing consumption of mushrooms such as golden, oyster, shiitake and white button mushrooms is associated with a reduced risk of mild cognitive impairment in elderly Singaporeans. Low ET levels are also associated with a number of other age-related diseases such as frailty, cardiovascular disease and macular degeneration, so ET may have a more general role in maintaining health.

An earlier study by the research team in 2016 showed lower ET levels in blood plasma among participants with mild cognitive impairment. This was verified in a much larger group of cognitively impaired participants with and without dementia. However, evidence of whether a low level of ET in blood plasma can predict the progression of cognitive impairment and dementia was unknown. The most recent study by the NUS research team addresses these gaps in ET research by demonstrating the potential of ET as a predictive biomarker for cognitive impairment and dementia in elderly Singaporeans.

In the latest study, the research team recruited 470 elderly patients and followed them for up to five years. The researchers measured ET levels in the blood plasma of the participants and followed their cognitive and functional abilities at different time points. They then examined the link between low ET levels and the risk of cognitive and functional decline over time. The researchers showed that participants with lower levels of ET displayed poorer cognitive performance at the start of the study and an accelerated rate of decline in cognitive and functional abilities over the follow-up period.

The team also observed structural changes in the brain seen from MRI (magnetic resonance imaging) scans of the participants, which suggested that the association between a low ET level in blood and cognitive decline was due to underlying disease pathology. These structural changes, including reduced cortical thickness, lower hippocampus volume, and white matter hyperintensities, are characteristic of neurodegenerative disease. Based on this study, which showed that plasma ET levels in the blood can be a predictive biomarker for the risk of cognitive and functional decline, the research team hopes to gather further evidence of ET’s preventive and therapeutic potential through a double-blinded placebo-controlled clinical trial.

"Before this study, there was little evidence that ET levels in the blood can predict the risk of developing cognitive issues. The current study is significant because it measured the ET levels of elderly participants before developing dementia. Our findings demonstrate that if your ET levels are low, your risk of developing cognitive problems increases,” said Professor Barry Halliwell from the Department of Biochemistry under the NUS Yong Loo Lin School of Medicine who led the research team. “This points to the possibility of using a simple blood test to detect ET levels for early screening in the elderly to identify those who may have higher risk of cognitive decline.”

Related Links:
NUS

Visit expo >

Platinum Member

COVID-19 Rapid Test

OSOM COVID-19 Antigen Rapid Test

Magnetic Bead Separation Modules
MAG and HEATMAG

Complement 3 (C3) Test

GPP-100 C3 Kit

Gold Member

Systemic Autoimmune Testing Assay

BioPlex 2200 ANA Screen with MDSS